A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse

G. Bianchi Porro, M. Lazzaroni, L. Barbara, R. Corinaldesi, A. Blasi, A. Mangiameli, L. Capurso, M. Koch, R. Cheli, E. Bovero, R. De Franchis, M. Guslandi, A. Francavilla, M. Ingrosso, G. Gasbarrini, G. Zoli, G. Mazzacca, F. Sabbatini, R. Naccarato

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A 24-week, double-blind, randomized study at 13 centres compared the efficacy and safety of 20 mg famotidine nocte and 150 mg ranitidine h.s. for the prevention of duodenal ulcer recurrence. All participants had been successfully treated for an acute duodenal ulcer with 40 mg famotidine nocte. Patients were endoscoped at baseline and at 24 weeks, unless symptoms warranted earlier examination: of the 208 patients enrolled, 86 who received famotidine and 84 who received ranitidine met all protocol criteria and were considered evaluable. Intention to treat and per protocol analyses showed non-significant trends in favour of famotidine (P = 0.44 and 0.16, respectively). During the 24-week observation period, 16.3% of the famotidine group and 25% of the ranitidine group had an ulcer recurrence (95% CI of percentage difference -0.22 + 0.04). At 24 weeks, relief of day and night pain was reported by 81.2% and 91.8% of the famotidine-treated patients, respectively. The corresponding figures in the ranitidine group were 73.5% and 85.5%. No laboratory abnormalities related to the study-drugs were noted and only two drug related (possibly or probably) adverse experiences were reported, both in the famotidine group. The data from this study therefore, supports the conclusion that the efficacy of 20 mg famotidine nocte is comparable to that of ranitidine in preventing duodenal ulcer recurrence, with comparable tolerability for long-term therapy.

Original languageEnglish
Pages (from-to)181-189
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume5
Issue number2
Publication statusPublished - 1991

Fingerprint

Famotidine
Ranitidine
Duodenal Ulcer
Recurrence
Double-Blind Method
Pharmaceutical Preparations
Ulcer
Observation
Safety
Pain

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Bianchi Porro, G., Lazzaroni, M., Barbara, L., Corinaldesi, R., Blasi, A., Mangiameli, A., ... Naccarato, R. (1991). A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse. Alimentary Pharmacology and Therapeutics, 5(2), 181-189.

A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse. / Bianchi Porro, G.; Lazzaroni, M.; Barbara, L.; Corinaldesi, R.; Blasi, A.; Mangiameli, A.; Capurso, L.; Koch, M.; Cheli, R.; Bovero, E.; De Franchis, R.; Guslandi, M.; Francavilla, A.; Ingrosso, M.; Gasbarrini, G.; Zoli, G.; Mazzacca, G.; Sabbatini, F.; Naccarato, R.

In: Alimentary Pharmacology and Therapeutics, Vol. 5, No. 2, 1991, p. 181-189.

Research output: Contribution to journalArticle

Bianchi Porro, G, Lazzaroni, M, Barbara, L, Corinaldesi, R, Blasi, A, Mangiameli, A, Capurso, L, Koch, M, Cheli, R, Bovero, E, De Franchis, R, Guslandi, M, Francavilla, A, Ingrosso, M, Gasbarrini, G, Zoli, G, Mazzacca, G, Sabbatini, F & Naccarato, R 1991, 'A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse', Alimentary Pharmacology and Therapeutics, vol. 5, no. 2, pp. 181-189.
Bianchi Porro G, Lazzaroni M, Barbara L, Corinaldesi R, Blasi A, Mangiameli A et al. A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse. Alimentary Pharmacology and Therapeutics. 1991;5(2):181-189.
Bianchi Porro, G. ; Lazzaroni, M. ; Barbara, L. ; Corinaldesi, R. ; Blasi, A. ; Mangiameli, A. ; Capurso, L. ; Koch, M. ; Cheli, R. ; Bovero, E. ; De Franchis, R. ; Guslandi, M. ; Francavilla, A. ; Ingrosso, M. ; Gasbarrini, G. ; Zoli, G. ; Mazzacca, G. ; Sabbatini, F. ; Naccarato, R. / A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse. In: Alimentary Pharmacology and Therapeutics. 1991 ; Vol. 5, No. 2. pp. 181-189.
@article{085fa82bf8084d71a291559db3e828bd,
title = "A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse",
abstract = "A 24-week, double-blind, randomized study at 13 centres compared the efficacy and safety of 20 mg famotidine nocte and 150 mg ranitidine h.s. for the prevention of duodenal ulcer recurrence. All participants had been successfully treated for an acute duodenal ulcer with 40 mg famotidine nocte. Patients were endoscoped at baseline and at 24 weeks, unless symptoms warranted earlier examination: of the 208 patients enrolled, 86 who received famotidine and 84 who received ranitidine met all protocol criteria and were considered evaluable. Intention to treat and per protocol analyses showed non-significant trends in favour of famotidine (P = 0.44 and 0.16, respectively). During the 24-week observation period, 16.3{\%} of the famotidine group and 25{\%} of the ranitidine group had an ulcer recurrence (95{\%} CI of percentage difference -0.22 + 0.04). At 24 weeks, relief of day and night pain was reported by 81.2{\%} and 91.8{\%} of the famotidine-treated patients, respectively. The corresponding figures in the ranitidine group were 73.5{\%} and 85.5{\%}. No laboratory abnormalities related to the study-drugs were noted and only two drug related (possibly or probably) adverse experiences were reported, both in the famotidine group. The data from this study therefore, supports the conclusion that the efficacy of 20 mg famotidine nocte is comparable to that of ranitidine in preventing duodenal ulcer recurrence, with comparable tolerability for long-term therapy.",
author = "{Bianchi Porro}, G. and M. Lazzaroni and L. Barbara and R. Corinaldesi and A. Blasi and A. Mangiameli and L. Capurso and M. Koch and R. Cheli and E. Bovero and {De Franchis}, R. and M. Guslandi and A. Francavilla and M. Ingrosso and G. Gasbarrini and G. Zoli and G. Mazzacca and F. Sabbatini and R. Naccarato",
year = "1991",
language = "English",
volume = "5",
pages = "181--189",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse

AU - Bianchi Porro, G.

AU - Lazzaroni, M.

AU - Barbara, L.

AU - Corinaldesi, R.

AU - Blasi, A.

AU - Mangiameli, A.

AU - Capurso, L.

AU - Koch, M.

AU - Cheli, R.

AU - Bovero, E.

AU - De Franchis, R.

AU - Guslandi, M.

AU - Francavilla, A.

AU - Ingrosso, M.

AU - Gasbarrini, G.

AU - Zoli, G.

AU - Mazzacca, G.

AU - Sabbatini, F.

AU - Naccarato, R.

PY - 1991

Y1 - 1991

N2 - A 24-week, double-blind, randomized study at 13 centres compared the efficacy and safety of 20 mg famotidine nocte and 150 mg ranitidine h.s. for the prevention of duodenal ulcer recurrence. All participants had been successfully treated for an acute duodenal ulcer with 40 mg famotidine nocte. Patients were endoscoped at baseline and at 24 weeks, unless symptoms warranted earlier examination: of the 208 patients enrolled, 86 who received famotidine and 84 who received ranitidine met all protocol criteria and were considered evaluable. Intention to treat and per protocol analyses showed non-significant trends in favour of famotidine (P = 0.44 and 0.16, respectively). During the 24-week observation period, 16.3% of the famotidine group and 25% of the ranitidine group had an ulcer recurrence (95% CI of percentage difference -0.22 + 0.04). At 24 weeks, relief of day and night pain was reported by 81.2% and 91.8% of the famotidine-treated patients, respectively. The corresponding figures in the ranitidine group were 73.5% and 85.5%. No laboratory abnormalities related to the study-drugs were noted and only two drug related (possibly or probably) adverse experiences were reported, both in the famotidine group. The data from this study therefore, supports the conclusion that the efficacy of 20 mg famotidine nocte is comparable to that of ranitidine in preventing duodenal ulcer recurrence, with comparable tolerability for long-term therapy.

AB - A 24-week, double-blind, randomized study at 13 centres compared the efficacy and safety of 20 mg famotidine nocte and 150 mg ranitidine h.s. for the prevention of duodenal ulcer recurrence. All participants had been successfully treated for an acute duodenal ulcer with 40 mg famotidine nocte. Patients were endoscoped at baseline and at 24 weeks, unless symptoms warranted earlier examination: of the 208 patients enrolled, 86 who received famotidine and 84 who received ranitidine met all protocol criteria and were considered evaluable. Intention to treat and per protocol analyses showed non-significant trends in favour of famotidine (P = 0.44 and 0.16, respectively). During the 24-week observation period, 16.3% of the famotidine group and 25% of the ranitidine group had an ulcer recurrence (95% CI of percentage difference -0.22 + 0.04). At 24 weeks, relief of day and night pain was reported by 81.2% and 91.8% of the famotidine-treated patients, respectively. The corresponding figures in the ranitidine group were 73.5% and 85.5%. No laboratory abnormalities related to the study-drugs were noted and only two drug related (possibly or probably) adverse experiences were reported, both in the famotidine group. The data from this study therefore, supports the conclusion that the efficacy of 20 mg famotidine nocte is comparable to that of ranitidine in preventing duodenal ulcer recurrence, with comparable tolerability for long-term therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025765304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025765304&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 181

EP - 189

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 2

ER -